Professor Andrew Biankin

  • Regius Chair of Surgery/Director of Translational Research Centre (Translational Research Centre)

Research interests

Andrew Biankin is a surgeon-scientist whose research goals are to improve outcomes for individuals with pancreatic cancer through the development of early detection and novel therapeutic strategies based on molecular phenotyping and the delineation and implementation of biomarkers that facilitate clinical decision-making. He contributes to the International Cancer Genome Consortium through extensively characterising the genomic, transcriptomic and epigenomic aberrations in pancreatic cancer, and is extending this knowledge to a personalized model of cancer care, where molecular characteristics guide treatment decisions.

Cancer Research UK Profile

Group Members

Eirini-Maria Lampraki. Research Assistant. Eirini-Maria.Lampraki@glasgow.ac.uk

Sarah Allison: Technican. Sarah.allison@glasgow.ac.uk

Maja Bailey: Research Fellow.  maja.bailey@glasgow.ac.uk

Dario Beraldi: Bioinformatician. Dario.beraldi@glasgow.ac.uk

Holly Brunton: Research Associate.  holly.brunton@glasgow.ac.uk

Giusy Caligiuri: PhD Student.  g.caligiuri.1@research.gla.ac.uk

David Chang: Clinical Senior Lecturer/GPOL Clinical Translational Development Lead. david.chang@glasgow.ac.uk

Susie Cooke: Bioinformatician/GPOL Informatics Lead. susie.cooke@glasgow.ac.uk

Ricky Cunningham: PhD Student.  r.cunningham.1@research.gla.ac.uk

Stephan Dreyer: Clinical Research Fellow.  stephan.dreyer@glasgow.ac.uk

John Marshall: Senior Software Developer/Bioinformatician. John.w.marshall@glasgow.ac.uk

Brian McDade: Technician. Brian.mcdade@glasgow.ac.uk

Daniel McElroy: LIMS/Data Manager. Daniel.mcelroy@glasgow.ac.uk

Bryan Serrels: Research Fellow. bryan.serrels@glasgow.ac.uk

Rosie Upstill-Goddard: Post Doc.  Rosie.Upstill-Goddard@glasgow.ac.uk

Shane Kelly: HPS Systems Administrator.  Shane.Kelly@glasgow.ac.uk

Paul Grimwood: Configuration Manager/Database Developer.  Paul.Grimwood@glasgow.ac.uk

Donna Ramsay: Quality Manager.  Donna.Ramsay@glasgow.ac.uk

Associates

Fraser Duthie: Consultant Pathologist. fraser.duthie@glasgow.ac.uk

Mark Duxbury. Consultant Hepatobiliary & Pancreatic Surgeon. MDuxbury@NHS.net Translational cancer research. Investigating the biology and clinical relevance of SIDT-family proteins in human cancer.

Janet Graham. Consultant Medical Oncologist and NRS Research Fellow BWOSCC. janet.graham@ggc.scot.nhs.uk

Nigel Jamieson: Clinical Lecturer in General Surgery (Medicine). Nigel.jamieson@glasgow.ac.uk

Ke Yuan: Lecturer in Computing Science (Machine Learning in Computational Biology). Ke.Yuan@glasgow.ac.uk


Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • ICGCmed involvement
    Cancer Research UK
    2017 - 2018
     
  • Precision Medicine Laboratory sequencing of patient tumour samples
    Beatson Cancer Charity
    2017 - 2022
     
  • Precision Panc
    Cancer Research UK
    2017 - 2019
     
  • CRUK Centre Renewal
    Cancer Research UK
    2017 - 2019
     
  • Developing new clinically relevant positron emission tomography (PET) probes in Glasgow
    Beatson Cancer Charity
    2017 - 2022
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • University of Glasgow Human Cancer Models Initiative Pilot: Clinical Hub
    Cancer Research UK
    2016 - 2018
     
  • The Scottish Genomes Partnership
    Chief Scientist Office
    2016 - 2019
     
  • Using preoperative pancreatic endoscopic ultrasound to enable precision medicine for the management of pancreatic cancer
    Pancreatic Cancer Research Fund
    2015 - 2017
     
  • Glasgow Molecular Pathology (GMP) Node
    Medical Research Council
    2015 - 2019
     
  • Clinical Training Award Cycle 2
    Cancer Research UK
    2015 - 2018
     
  • Defining Platinum and PARP Responsive Molecular Phenotypes of Pancreatic Cancer.
    Wellcome Trust
    2015 - 2020
     
  • Italian pancreatic cancer genome initiative
    ARC - NET Centre for Applied Research on Cancer
    2015 - 2019
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2020
     
  • CR-UK Centre renewal
    Cancer Research UK
    2014 - 2017
     
  • Genotype Guided Stratified Therapy for Pancreatic Cancer
    Cancer Research UK
    2014 - 2019
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
Number of items: 91.

2018

Shroff, R. T. et al. (2018) Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncology, (doi:10.1200/po.17.00316) (Early Online Publication)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23(5), pp. 1448-1460. (doi:10.1016/j.celrep.2018.03.131) (PMID:29719257)

Sheahan, A. V., Biankin, A. V. , Parish, C. R. and Khachigian, L. M. (2018) Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 9(30), pp. 21613-21627. (doi:10.18632/oncotarget.25085)

Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin, A. V. , Scholten, R. J.P.M. and Yip, D. (2018) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, 2018(3), CD011044. (doi:10.1002/14651858.cd011044.pub2) (PMID:29557103)

Grant, R. C. et al. (2018) Exome-wide association study of pancreatic cancer risk. Gastroenterology, 154(3), 719-722.e3. (doi:10.1053/j.gastro.2017.10.015) (PMID:29074453)

Dreyer, S.B., Jamieson, N.B., Upstill-Goddard, R., Bailey, P.J., McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi:10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

2017

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi:10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi:10.1038/nature24462) (PMID:29132146)

Chou, A. et al. (2017) Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, (doi:10.1136/gutjnl-2017-315144) (PMID:29080858) (Early Online Publication)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi:10.1038/nature24026) (PMID:28953865)

Raphael, B. J. et al. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell, 32(2), 185-203.e13. (doi:10.1016/j.ccell.2017.07.007) (PMID:28810144)

Harris, N.L.E. et al. (2017) SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene, 36(30), pp. 4288-4298. (doi:10.1038/onc.2017.63) (PMID:28346421) (PMCID:PMC5537606)

Feigin, M. E. et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 49(6), pp. 825-833. (doi:10.1038/ng.3861) (PMID:28481342) (PMCID:PMC5659388)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi:10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Jung, L.A. et al. (2017) OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene, 36(14), pp. 1911-1924. (doi:10.1038/onc.2016.354) (PMID:27748763)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi:10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

Pishvaian, M. J., Biankin, A. V. , Bailey, P., Chang, D. K. , Laheru, D., Wolfgang, C. L. and Brody, J. R. (2017) BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 116, pp. 1021-1026. (doi:10.1038/bjc.2017.40) (PMID:28291774)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi:10.1038/nature21063) (PMID:28199314)

Biankin, A. V. (2017) The road to precision oncology. Nature Genetics, 49(3), pp. 320-321. (doi:10.1038/ng.3796) (PMID:28232728)

Vallejo, A. et al. (2017) An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 8, 14294. (doi:10.1038/ncomms14294) (PMID:28220783) (PMCID:PMC5321758)

Hardie, R.-A. et al. (2017) Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer and Metabolism, 5, 2. (doi:10.1186/s40170-017-0164-1) (PMID:28163917) (PMCID:PMC5282905)

Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 254-268. (doi:10.1038/nrc.2016.140) (PMID:28104906)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

Martinelli, P. et al. (2017) GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66, pp. 1665-1676. (doi:10.1136/gutjnl-2015-311256) (PMID:27325420) (PMCID:PMC5070637)

2016

Sharbeen, G., Youkhana, J., Mawson, A., McCarroll, J., Nunez, A., Biankin, A. , Johns, A., Goldstein, D. and Phillips, P. (2016) MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget, 8(6), pp. 9216-9229. (doi:10.18632/oncotarget.13985) (PMID:27999205)

Roy, N. et al. (2016) PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes and Development, 30(24), pp. 2669-2683. (doi:10.1101/gad.291021.116) (PMID:28087712)

Sharbeen, G., McCarroll, J., Liu, J., Youkhana, J., Limbri, L.F., Biankin, A.V. , Johns, A., Kavallaris, M., Goldstein, D. and Phillips, P.A. (2016) Delineating the role of βIV-Tubulins in pancreatic cancer: βIVb-tubulin inhibition sensitizes pancreatic cancer cells to vinca alkaloids. Neoplasia, 18(12), pp. 753-764. (doi:10.1016/j.neo.2016.10.011) (PMID:27889644) (PMCID:PMC5126129)

Bailey, P. et al. (2016) Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 6, 35848. (doi:10.1038/srep35848) (PMID:27762323) (PMCID:PMC5071896)

Humphrey, E. S. et al. (2016) Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Molecular and Cellular Proteomics, 15(8), pp. 2671-2685. (doi:10.1074/mcp.M116.058313) (PMID:27259358) (PMCID:PMC4974343)

Swanton, C. et al. (2016) Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 27(8), pp. 1443-1448. (doi:10.1093/annonc/mdw192) (PMID:27143638)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Kleeff, J. et al. (2016) Pancreatic cancer. Nature Reviews Disease Primers, 2, 16022. (doi:10.1038/nrdp.2016.22) (PMID:27158978)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi:10.1038/nature16965) (PMID:26909576)

Humphris, J. L. and Biankin, A. V. (2016) Diagnosis and management of hereditary pancreatic cancer. In: Pichert, G. and Jacobs, C. (eds.) Rare Hereditary Cancers: Diagnosis and Management. Series: Recent results in cancer research (205). Springer International Publishing: Cham, pp. 61-83. ISBN 9783319299969 (doi:10.1007/978-3-319-29998-3_5)

2015

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A. and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 96(3), pp. 483-497. (doi:10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Jamieson, N. B., Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B., Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi:10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Susanto, J. M. et al. (2015) The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 46(5), pp. 2223-30. (doi:10.3892/ijo.2015.2894) (PMID:25695794)

Carlino, M.S. et al. (2015) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Journal of Clinical Oncology, 33(11), e52-e56. (doi:10.1200/JCO.2013.51.5783) (PMID:24821886)

Humphris, J., Chang, D. K. and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi:10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Biankin, A. V. , Piantadosi, S. and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi:10.1038/nature15819) (PMID:26469047)

Chin, V., Nagrial, A., Chou, A., Biankin, A. V. , Gill, A., Timpson, P. and Pajic, M. (2015) Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, e17. (doi:10.1017/erm.2015.17) (PMID:26507949)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Tactacan, C.M., Phua, Y.W., Liu, L., Zhang, L., Humphrey, E.S., Cowley, M., Pinese, M., Biankin, A.V. and Daly, R.J. (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer, 14, 139. (doi:10.1186/s12943-015-0412-3) (PMID:26215634) (PMCID:PMC4517651)

2014

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi:10.1002/cncr.28863) (PMID:25313458)

Hudson, A. M., Yates, T., Li, Y., Trotter, E. W., Fawdar, S., Chapman, P., Lorigan, P., Biankin, A. , Miller, C. J. and Brognard, J. (2014) Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research, 74(22), pp. 6390-6396. (doi:10.1158/0008-5472.CAN-14-1020) (PMID:25256751)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi:10.1002/ijc.28765) (PMID:24500968)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Quek, K. et al. (2014) A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. BioTechniques, 57(1), pp. 31-38. (doi:10.2144/000114189)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi:10.3748/wjg.v20.i24.7849) (PMID:24976722) (PMCID:PMC4069313)

Al-Ejeh, F. et al. (2014) Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), pp. 3187-3197. (doi:10.1158/1078-0432.CCR-14-0048) (PMID:24838526)

Johns, A. L. et al. (2014) Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 6(5), 42. (doi:10.1186/gm558) (PMID:24963353) (PMCID:PMC4067993)

Jamieson, N. B., Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820) (PMID:24702631)

Weissmueller, S. et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell, 157(2), pp. 382-394. (doi:10.1016/j.cell.2014.01.066)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi:10.1016/j.gde.2013.12.001) (PMID:24480245)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi:10.1038/bjc.2013.722) (PMID:24263063) (PMCID:PMC3899761)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723) (PMID:25688402)

Chang, D. K. , Jamieson, N. B., Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi:10.1016/B978-0-12-386882-4.00034-7)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi:10.1158/2159-8290.CD-14-0001)

Jamieson, N. B., Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

2013

Chang, D. K. , Jamieson, N. B., Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi:10.1200/JCO.2013.51.3176) (PMID:24043730)

Cowley, M.J., Chang, D.K. , Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M. and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi:10.1007/s00534-013-0610-6) (PMID:23660961)

Cao, Y. et al. (2013) Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial 5 integrin. Cancer Research, 73(14), pp. 4579-4590. (doi:10.1158/0008-5472.CAN-13-0529) (PMID:23689123) (PMCID:PMC3774599)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi:10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi:10.1186/gm482) (PMID:24004612) (PMCID:PMC3978667)

Liu, P.Y. et al. (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 20(3), pp. 503-514. (doi:10.1038/cdd.2012.147) (PMID:23175188) (PMCID:PMC3569991)

2012

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi:10.1038/nature11547) (PMID:23103869) (PMCID:PMC3530898)

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi:10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi:10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi:10.1093/annonc/mdr561) (PMID:22241899) (PMCID:PMC3387824)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi:10.1073/pnas.1202490109) (PMID:2242144) (PMCID:PMC1663246)

2011

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi:10.1371/journal.pone.0029075) (PMID:22220202) (PMCID:PMC3248409)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2011) Molecular diagnostics in pancreatic cancer. In: Friess, H. and Hüser, N. (eds.) Advances in Pancreatic Cancer Treatment. Future Medicine Ltd., pp. 20-35. ISBN 9781780840703

Scarlett, C. J. et al. (2011) Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS ONE, 6(10), e26088. (doi:10.1371/journal.pone.0026088) (PMID:22022519)

Nguyen, N. Q. et al. (2011) Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. Journal of Gastroenterology and Hepatology, 26(2), pp. 267-274. (doi:10.1111/j.1440-1746.2010.06466.x) (PMID:21261715)

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi:10.1016/j.stem.2011.10.002)

2010

Marshall, G.M. et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 29(44), pp. 5957-5968. (doi:10.1038/onc.2010.332) (PMID:20697349)

2009

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi:10.1200/JCO.2008.20.5104) (PMID:19398572)

Nguyen, N. Q., Biankin, A. V. , Leong, R. W. L., Chang, D. K. , Cosman, P. H., Delaney, P., Kench, J. G. and Merrett, N. D. (2009) Real time intraoperative confocal laser microscopy-guided surgery. Annals of Surgery, 249(5), pp. 735-737. (doi:10.1097/SLA.0b013e3181a38f11) (PMID:19387332)

Gill, A. J. et al. (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), pp. 161-167. (doi:10.1080/00313020802337329) (PMID:19320058)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi:10.1053/j.gastro.2009.04.009) (PMID:19376121)

Chang, D. K. , Nguyen, N. Q., Merrett, N. D., Dixson, H., Leong, R. W.L. and Biankin, A. V. (2009) Role of endoscopic ultrasound in pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 3(3), pp. 293-303. (doi:10.1586/egh.09.18) (PMID:19485810)

2008

Colvin, E. K., Chang, D. K. , Merrett, N. D., Kench, J. G. and Biankin, A. V. (2008) Individualizing therapy for pancreatic cancer. Journal of Gastroenterology and Hepatology, 23(12), pp. 1779-1782. (doi:10.1111/j.1440-1746.2008.05683.x) (PMID:19120869)

Chang, D. K. , Merrett, N. D. and Biankin, A. V. (2008) Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem? Journal of Gastroenterology and Hepatology, 23(7pt1), pp. 1036-1045. (doi:10.1111/j.1440-1746.2008.05471.x) (PMID:18707598)

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi:10.1038/sj.bjc.6604177)

Leong, R.W.L., Nguyen, N.Q., Meredith, C.G., Al–Sohaily, S., Kukic, D., Delaney, P.M., Murr, E.R., Yong, J., Merrett, N.D. and Biankin, A.V. (2008) In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology, 135(6), pp. 1870-1876. (doi:10.1053/j.gastro.2008.08.054)

This list was generated on Tue Sep 25 13:58:27 2018 BST.
Number of items: 91.

Articles

Shroff, R. T. et al. (2018) Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncology, (doi:10.1200/po.17.00316) (Early Online Publication)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23(5), pp. 1448-1460. (doi:10.1016/j.celrep.2018.03.131) (PMID:29719257)

Sheahan, A. V., Biankin, A. V. , Parish, C. R. and Khachigian, L. M. (2018) Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 9(30), pp. 21613-21627. (doi:10.18632/oncotarget.25085)

Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin, A. V. , Scholten, R. J.P.M. and Yip, D. (2018) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, 2018(3), CD011044. (doi:10.1002/14651858.cd011044.pub2) (PMID:29557103)

Grant, R. C. et al. (2018) Exome-wide association study of pancreatic cancer risk. Gastroenterology, 154(3), 719-722.e3. (doi:10.1053/j.gastro.2017.10.015) (PMID:29074453)

Dreyer, S.B., Jamieson, N.B., Upstill-Goddard, R., Bailey, P.J., McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi:10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi:10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi:10.1038/nature24462) (PMID:29132146)

Chou, A. et al. (2017) Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, (doi:10.1136/gutjnl-2017-315144) (PMID:29080858) (Early Online Publication)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi:10.1038/nature24026) (PMID:28953865)

Raphael, B. J. et al. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell, 32(2), 185-203.e13. (doi:10.1016/j.ccell.2017.07.007) (PMID:28810144)

Harris, N.L.E. et al. (2017) SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene, 36(30), pp. 4288-4298. (doi:10.1038/onc.2017.63) (PMID:28346421) (PMCID:PMC5537606)

Feigin, M. E. et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 49(6), pp. 825-833. (doi:10.1038/ng.3861) (PMID:28481342) (PMCID:PMC5659388)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi:10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Jung, L.A. et al. (2017) OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene, 36(14), pp. 1911-1924. (doi:10.1038/onc.2016.354) (PMID:27748763)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi:10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

Pishvaian, M. J., Biankin, A. V. , Bailey, P., Chang, D. K. , Laheru, D., Wolfgang, C. L. and Brody, J. R. (2017) BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 116, pp. 1021-1026. (doi:10.1038/bjc.2017.40) (PMID:28291774)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi:10.1038/nature21063) (PMID:28199314)

Biankin, A. V. (2017) The road to precision oncology. Nature Genetics, 49(3), pp. 320-321. (doi:10.1038/ng.3796) (PMID:28232728)

Vallejo, A. et al. (2017) An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 8, 14294. (doi:10.1038/ncomms14294) (PMID:28220783) (PMCID:PMC5321758)

Hardie, R.-A. et al. (2017) Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer and Metabolism, 5, 2. (doi:10.1186/s40170-017-0164-1) (PMID:28163917) (PMCID:PMC5282905)

Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 254-268. (doi:10.1038/nrc.2016.140) (PMID:28104906)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

Martinelli, P. et al. (2017) GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66, pp. 1665-1676. (doi:10.1136/gutjnl-2015-311256) (PMID:27325420) (PMCID:PMC5070637)

Sharbeen, G., Youkhana, J., Mawson, A., McCarroll, J., Nunez, A., Biankin, A. , Johns, A., Goldstein, D. and Phillips, P. (2016) MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget, 8(6), pp. 9216-9229. (doi:10.18632/oncotarget.13985) (PMID:27999205)

Roy, N. et al. (2016) PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes and Development, 30(24), pp. 2669-2683. (doi:10.1101/gad.291021.116) (PMID:28087712)

Sharbeen, G., McCarroll, J., Liu, J., Youkhana, J., Limbri, L.F., Biankin, A.V. , Johns, A., Kavallaris, M., Goldstein, D. and Phillips, P.A. (2016) Delineating the role of βIV-Tubulins in pancreatic cancer: βIVb-tubulin inhibition sensitizes pancreatic cancer cells to vinca alkaloids. Neoplasia, 18(12), pp. 753-764. (doi:10.1016/j.neo.2016.10.011) (PMID:27889644) (PMCID:PMC5126129)

Bailey, P. et al. (2016) Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 6, 35848. (doi:10.1038/srep35848) (PMID:27762323) (PMCID:PMC5071896)

Humphrey, E. S. et al. (2016) Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Molecular and Cellular Proteomics, 15(8), pp. 2671-2685. (doi:10.1074/mcp.M116.058313) (PMID:27259358) (PMCID:PMC4974343)

Swanton, C. et al. (2016) Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 27(8), pp. 1443-1448. (doi:10.1093/annonc/mdw192) (PMID:27143638)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Kleeff, J. et al. (2016) Pancreatic cancer. Nature Reviews Disease Primers, 2, 16022. (doi:10.1038/nrdp.2016.22) (PMID:27158978)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi:10.1038/nature16965) (PMID:26909576)

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A. and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 96(3), pp. 483-497. (doi:10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Jamieson, N. B., Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B., Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi:10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Susanto, J. M. et al. (2015) The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 46(5), pp. 2223-30. (doi:10.3892/ijo.2015.2894) (PMID:25695794)

Carlino, M.S. et al. (2015) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Journal of Clinical Oncology, 33(11), e52-e56. (doi:10.1200/JCO.2013.51.5783) (PMID:24821886)

Humphris, J., Chang, D. K. and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi:10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Biankin, A. V. , Piantadosi, S. and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi:10.1038/nature15819) (PMID:26469047)

Chin, V., Nagrial, A., Chou, A., Biankin, A. V. , Gill, A., Timpson, P. and Pajic, M. (2015) Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, e17. (doi:10.1017/erm.2015.17) (PMID:26507949)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Tactacan, C.M., Phua, Y.W., Liu, L., Zhang, L., Humphrey, E.S., Cowley, M., Pinese, M., Biankin, A.V. and Daly, R.J. (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer, 14, 139. (doi:10.1186/s12943-015-0412-3) (PMID:26215634) (PMCID:PMC4517651)

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi:10.1002/cncr.28863) (PMID:25313458)

Hudson, A. M., Yates, T., Li, Y., Trotter, E. W., Fawdar, S., Chapman, P., Lorigan, P., Biankin, A. , Miller, C. J. and Brognard, J. (2014) Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research, 74(22), pp. 6390-6396. (doi:10.1158/0008-5472.CAN-14-1020) (PMID:25256751)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi:10.1002/ijc.28765) (PMID:24500968)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Quek, K. et al. (2014) A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. BioTechniques, 57(1), pp. 31-38. (doi:10.2144/000114189)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi:10.3748/wjg.v20.i24.7849) (PMID:24976722) (PMCID:PMC4069313)

Al-Ejeh, F. et al. (2014) Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), pp. 3187-3197. (doi:10.1158/1078-0432.CCR-14-0048) (PMID:24838526)

Johns, A. L. et al. (2014) Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 6(5), 42. (doi:10.1186/gm558) (PMID:24963353) (PMCID:PMC4067993)

Jamieson, N. B., Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820) (PMID:24702631)

Weissmueller, S. et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell, 157(2), pp. 382-394. (doi:10.1016/j.cell.2014.01.066)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi:10.1016/j.gde.2013.12.001) (PMID:24480245)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi:10.1038/bjc.2013.722) (PMID:24263063) (PMCID:PMC3899761)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723) (PMID:25688402)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi:10.1158/2159-8290.CD-14-0001)

Chang, D. K. , Jamieson, N. B., Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi:10.1200/JCO.2013.51.3176) (PMID:24043730)

Cowley, M.J., Chang, D.K. , Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M. and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi:10.1007/s00534-013-0610-6) (PMID:23660961)

Cao, Y. et al. (2013) Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial 5 integrin. Cancer Research, 73(14), pp. 4579-4590. (doi:10.1158/0008-5472.CAN-13-0529) (PMID:23689123) (PMCID:PMC3774599)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi:10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi:10.1186/gm482) (PMID:24004612) (PMCID:PMC3978667)

Liu, P.Y. et al. (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 20(3), pp. 503-514. (doi:10.1038/cdd.2012.147) (PMID:23175188) (PMCID:PMC3569991)

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi:10.1038/nature11547) (PMID:23103869) (PMCID:PMC3530898)

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi:10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi:10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi:10.1093/annonc/mdr561) (PMID:22241899) (PMCID:PMC3387824)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi:10.1073/pnas.1202490109) (PMID:2242144) (PMCID:PMC1663246)

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi:10.1371/journal.pone.0029075) (PMID:22220202) (PMCID:PMC3248409)

Scarlett, C. J. et al. (2011) Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS ONE, 6(10), e26088. (doi:10.1371/journal.pone.0026088) (PMID:22022519)

Nguyen, N. Q. et al. (2011) Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. Journal of Gastroenterology and Hepatology, 26(2), pp. 267-274. (doi:10.1111/j.1440-1746.2010.06466.x) (PMID:21261715)

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi:10.1016/j.stem.2011.10.002)

Marshall, G.M. et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 29(44), pp. 5957-5968. (doi:10.1038/onc.2010.332) (PMID:20697349)

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi:10.1200/JCO.2008.20.5104) (PMID:19398572)

Nguyen, N. Q., Biankin, A. V. , Leong, R. W. L., Chang, D. K. , Cosman, P. H., Delaney, P., Kench, J. G. and Merrett, N. D. (2009) Real time intraoperative confocal laser microscopy-guided surgery. Annals of Surgery, 249(5), pp. 735-737. (doi:10.1097/SLA.0b013e3181a38f11) (PMID:19387332)

Gill, A. J. et al. (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), pp. 161-167. (doi:10.1080/00313020802337329) (PMID:19320058)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi:10.1053/j.gastro.2009.04.009) (PMID:19376121)

Chang, D. K. , Nguyen, N. Q., Merrett, N. D., Dixson, H., Leong, R. W.L. and Biankin, A. V. (2009) Role of endoscopic ultrasound in pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 3(3), pp. 293-303. (doi:10.1586/egh.09.18) (PMID:19485810)

Colvin, E. K., Chang, D. K. , Merrett, N. D., Kench, J. G. and Biankin, A. V. (2008) Individualizing therapy for pancreatic cancer. Journal of Gastroenterology and Hepatology, 23(12), pp. 1779-1782. (doi:10.1111/j.1440-1746.2008.05683.x) (PMID:19120869)

Chang, D. K. , Merrett, N. D. and Biankin, A. V. (2008) Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem? Journal of Gastroenterology and Hepatology, 23(7pt1), pp. 1036-1045. (doi:10.1111/j.1440-1746.2008.05471.x) (PMID:18707598)

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi:10.1038/sj.bjc.6604177)

Leong, R.W.L., Nguyen, N.Q., Meredith, C.G., Al–Sohaily, S., Kukic, D., Delaney, P.M., Murr, E.R., Yong, J., Merrett, N.D. and Biankin, A.V. (2008) In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology, 135(6), pp. 1870-1876. (doi:10.1053/j.gastro.2008.08.054)

Book Sections

Humphris, J. L. and Biankin, A. V. (2016) Diagnosis and management of hereditary pancreatic cancer. In: Pichert, G. and Jacobs, C. (eds.) Rare Hereditary Cancers: Diagnosis and Management. Series: Recent results in cancer research (205). Springer International Publishing: Cham, pp. 61-83. ISBN 9783319299969 (doi:10.1007/978-3-319-29998-3_5)

Chang, D. K. , Jamieson, N. B., Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi:10.1016/B978-0-12-386882-4.00034-7)

Jamieson, N. B., Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2011) Molecular diagnostics in pancreatic cancer. In: Friess, H. and Hüser, N. (eds.) Advances in Pancreatic Cancer Treatment. Future Medicine Ltd., pp. 20-35. ISBN 9781780840703

This list was generated on Tue Sep 25 13:58:27 2018 BST.